Limoge TCES Device
Chronic Pain Management & Opioid Dose Reduction
Key Facts
About FutraMed
FutraMed is a clinical-stage medical device company focused on addressing the opioid crisis through its patented Limoge TCES (Transcutaneous Cranial Electrical Stimulation) device. The technology, based on decades of research by Dr. Aimé Limoge, is designed to potentiate the effects of opioids, allowing for dose reduction and alleviation of withdrawal symptoms, thereby targeting both chronic pain management and opioid use disorder. The company holds a CE Mark (2020) for commercialization in Europe and a U.S. patent but is not yet authorized for sale in the USA, and is actively seeking investment to advance commercialization efforts.
View full company profileAbout FutraMed
FutraMed is a clinical-stage medical device company focused on addressing the opioid crisis through its patented Limoge TCES (Transcutaneous Cranial Electrical Stimulation) device. The technology, based on decades of research by Dr. Aimé Limoge, is designed to potentiate the effects of opioids, allowing for dose reduction and alleviation of withdrawal symptoms, thereby targeting both chronic pain management and opioid use disorder. The company holds a CE Mark (2020) for commercialization in Europe and a U.S. patent but is not yet authorized for sale in the USA, and is actively seeking investment to advance commercialization efforts.
View full company profile